BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27006202)

  • 1. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography/triple quadrupole mass spectrometry.
    Murase T; Oka M; Nampei M; Miyachi A; Nakamura T
    J Labelled Comp Radiopharm; 2016 May; 59(5):214-20. PubMed ID: 27006202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
    Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry.
    Murase T; Nampei M; Oka M; Ashizawa N; Matsumoto K; Miyachi A; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():189-197. PubMed ID: 26673227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
    Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
    Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
    Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
    Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
    Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
    Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population.
    Furuhashi M; Matsumoto M; Tanaka M; Moniwa N; Murase T; Nakamura T; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Circ J; 2018 Jun; 82(7):1892-1899. PubMed ID: 29643318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xanthine oxidoreductase activity is correlated with hepatic steatosis.
    Yagi C; Kusunoki Y; Tsunoda T; Murase T; Nakamura T; Osugi K; Ohigashi M; Morimoto A; Miyoshi A; Kakutani-Hatayama M; Kosaka-Hamamoto K; Kadoya M; Konishi K; Shoji T; Koyama H
    Sci Rep; 2022 Jul; 12(1):12282. PubMed ID: 35854080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xanthine oxidoreductase activity in marathon runners: potential implications for marathon-induced acute kidney injury.
    Kosaki K; Kumamoto S; Tokinoya K; Yoshida Y; Sugaya T; Murase T; Akari S; Nakamura T; Nabekura Y; Takekoshi K; Maeda S
    J Appl Physiol (1985); 2022 Jul; 133(1):1-10. PubMed ID: 35608201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
    Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
    Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases.
    Sato K; Naganuma A; Nagashima T; Arai Y; Mikami Y; Nakajima Y; Kanayama Y; Murakami T; Uehara S; Uehara D; Yamazaki Y; Murase T; Nakamura T; Uraoka T
    Biomedicines; 2023 May; 11(5):. PubMed ID: 37239117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
    Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
    PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry.
    Kurajoh M; Fukumoto S; Akari S; Murase T; Nakamura T; Ihara Y; Imai T; Nagata Y; Morioka T; Mori K; Imanishi Y; Watanabe T; Emoto M
    Int J Cardiol Heart Vasc; 2023 Oct; 48():101264. PubMed ID: 37680549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
    Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
    Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment.
    Kawachi Y; Fujishima Y; Nishizawa H; Nagao H; Nakamura T; Akari S; Murase T; Taya N; Omori K; Miyake A; Fukuda S; Takahara M; Kita S; Katakami N; Maeda N; Shimomura I
    J Diabetes Investig; 2021 Aug; 12(8):1512-1520. PubMed ID: 33211396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of (13) C2 (15) N2 -labeled anti-inflammatory and cytoprotective tricyclic bis(cyanoenone) ([(13) C2 (15) N2 ]-TBE-31) as an internal standard for quantification by stable isotope dilution LC-MS method.
    Zheng S; Huang JT; Knatko EV; Sharp S; Higgins M; Ojima I; Dinkova-Kostova AT; Honda T
    J Labelled Comp Radiopharm; 2014 Aug; 57(10):606-10. PubMed ID: 25196444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees.
    Kurajoh M; Fukumoto S; Akari S; Murase T; Nakamura T; Takahashi K; Yoshida H; Nakatani S; Tsuda A; Morioka T; Mori K; Imanishi Y; Hirata K; Emoto M
    Sci Rep; 2022 Jun; 12(1):10281. PubMed ID: 35717455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens.
    Carro MD; Falkenstein E; Radke WJ; Klandorf H
    Comp Biochem Physiol C Toxicol Pharmacol; 2010 Jan; 151(1):12-7. PubMed ID: 19654053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.